Allergy Therapeutics’ full-year results for the year ending 30 June 2018 showed an adjusted LBT of £5.9m (vs -£1.3m in FY 2017), which was £3m better than forecast and helped by phasing of R&D spend. Key drivers were growing market share (+100bps) and rising gross margins (290bps) despite the weak allergy season. This led to pre-R&D EBIT rising 26% to £9.3m. We keenly await the outcome of the Phase III PQ Birch allergy trial, the results of which are due
